...
JIANPAI lab case study cover: yellow vitamin pellets, first-trial process success from a customer sample
Yellow Vitamin Pellets Case Study: First-Trial Process Success
A customer needed yellow vitamin pellets for a capsule product, and sent only a finished sample. There...
CIPM 2026 Q&A cover: pellet and 3-in-1 granulation at JIANPAI booth
CIPM 2026 Q&A: Centrifugal Granulation vs. Extrusion and the 3-in-1 Granulator
From October 27 to 29, 2026, the 68th China National Pharmaceutical Machinery Expo (CIPM 2026) filled...
CIPM 2026 Q&A cover: smart OSD, mixing and coating at JIANPAI booth 2-B27
CIPM 2026 Q&A: Smart OSD Manufacturing, Triple-Eccentric Mixing and Coating
At CIPM 2026 in Xiamen (October 27-29, 2026), visitors to JIANPAI Booth 2-B27 did not ask for brochures....
JianPai Technology team at CIPM 2026 Xiamen
JianPai Technology Concludes Successful Participation at CIPM 2026 Xiamen
JianPai Technology wraps up CIPM 2026 Xiamen at Booth 2-B27 (Oct 27–29): fluid bed and high-shear granulators,...

ABOUT US

About Us - Introducing our team,
mission, and values.

2026 Global Top 50 Pharma Companies Ranking (by 2025 Rx Sales)

2026 Global Top 50 Pharma Companies Ranking (by 2025 Rx Sales)

The global pharmaceutical industry continues to experience strong growth driven by innovation in biologics, oncology, diabetes and obesity treatment, vaccines, and rare disease therapies. In August 2026, Pharm Exec magazine published the 2026 Pharm Exec 50, ranking the Top 50 pharmaceutical companies worldwide by prescription drug (Rx) sales in fiscal year 2025.

This ranking is widely regarded as one of the most authoritative industry benchmarks, offering valuable insight for pharmaceutical manufacturers, API and packaging suppliers, pharmaceutical equipment companies, and distributors and contract manufacturing organizations (CMOs).

Below is the fully updated 2026 Global Top 50 Pharmaceutical Companies List, based on 2025 Rx sales.

Ranking Methodology

  • Ranking Source: Pharm Exec magazine (2026 Pharm Exec 50, published August 14, 2026)
  • Ranking Basis: Global prescription drug (Rx) sales
  • Fiscal Year: 2025
  • Ranking Release Year: 2026

This ranking reflects real commercial performance, not market capitalization or valuation. Figures in the table are 2025 Rx sales, shown in US$ billion.

2026 Global Top 50 Pharmaceutical Companies (Complete List)

Rank Company Headquarters 2025 Rx sales (US$ billion)
1 Eli Lilly USA 60.78
2 Johnson & Johnson USA 59.33
3 AbbVie USA 58.27
4 Roche Switzerland 57.51
5 AstraZeneca UK 55.04
6 Merck & Co. (MSD) USA 54.69
7 Novartis Switzerland 54.33
8 Pfizer USA 49.91
9 Sanofi France 48.97
10 Bristol-Myers Squibb USA 47.75
11 Novo Nordisk Denmark 46.80
12 GSK (GlaxoSmithKline) UK 42.72
13 Amgen USA 34.95
14 Takeda Japan 29.67
15 Gilead Sciences USA 28.83
16 Boehringer Ingelheim Germany 23.82
17 Bayer Germany 19.19
18 CSL Australia 15.44
19 Viatris USA 14.09
20 Teva Israel 14.08
21 Astellas Japan 12.60
22 Daiichi Sankyo Japan 12.04
23 Vertex Pharmaceuticals USA 11.97
24 Sandoz Group Switzerland 11.09
25 Otsuka Holdings Japan 9.87
26 Merck KGaA Germany 9.73
27 UCB Belgium 8.24
28 Grifols Spain 7.33
29 Biogen USA 7.12
30 Sun Pharma India 6.44
31 Regeneron USA 6.31
32 Organon USA 6.06
33 Yunnan Baiyao China 5.72
34 Abbott USA 5.51
35 Servier France 5.44
36 Bausch Health Canada 5.41
37 BeOne Medicines (formerly BeiGene) Switzerland 5.28
38 Fresenius Germany 5.21
39 Shanghai Pharmaceuticals China 5.16
40 Eisai Japan 4.78
41 Sino Biopharmaceutical Hong Kong 4.37
42 Menarini Italy 4.36
43 Incyte USA 4.35
44 Ipsen France 4.16
45 argenx Netherlands 4.15
46 Jazz Pharmaceuticals Ireland 4.02
47 STADA Germany 4.02
48 Huadong Medicine China 3.97
49 Jiangsu Hengrui Medicine China 3.85
50 Haleon UK 3.60

Data source: Pharm Exec, 2026 Pharm Exec 50 (FY 2025 prescription drug sales). Company names use common English forms; BeOne Medicines appears under its current name (formerly BeiGene).

Key Industry Trends from the 2026 Ranking

1. Eli Lilly Rises to No. 1

The headline change this year is Eli Lilly’s jump from No. 11 in the previous ranking to No. 1, with about $60.8 billion in 2025 Rx sales, up roughly 49% year over year. Johnson & Johnson, last year’s leader, is now No. 2. AbbVie, Roche, and AstraZeneca complete the top five.

2. U.S. Companies Continue to Lead by Count

Fifteen companies in the Top 50 are headquartered in the United States, still the largest national group, with particular strength in oncology, immunology, biologics, and metabolic disease, including GLP-1 therapies.

3. Switzerland, Japan, and Germany Remain Innovation Hubs

Switzerland is represented by Roche, Novartis, Sandoz, and BeOne Medicines (formerly BeiGene, now listed with a Swiss headquarters). Japan remains well represented by Takeda, Astellas, Daiichi Sankyo, Otsuka, and Eisai. Germany includes Boehringer Ingelheim, Bayer, Merck KGaA, Fresenius, and STADA.

4. China Holds Five Places; India Is Represented by Sun Pharma

Five Chinese companies are in this year’s list if Sino Biopharmaceutical (Hong Kong) is included: Yunnan Baiyao, Shanghai Pharmaceuticals (a new entrant), Sino Biopharmaceutical, Huadong Medicine, and Jiangsu Hengrui Medicine. CSPC Pharmaceutical Group is no longer in the Top 50. From India, Sun Pharma remains on the list; Dr. Reddy’s Laboratories is not in this year’s Top 50. New global entrants also include argenx (Netherlands) and Haleon (UK).

Why This Ranking Matters for Pharmaceutical Suppliers

If you are involved in pharmaceutical machinery manufacturing, packaging solutions (vials, bottles, blister, ampoules), API and excipient supply, or contract manufacturing (CDMO/CMO), this list directly reflects where purchasing power is concentrated, which companies control global drug production, and who your most valuable long-term customers may be.

Outlook for the Global Pharmaceutical Industry in 2026

Based on this ranking, the pharmaceutical industry will continue focusing on biologics and biosimilars, GLP-1 diabetes and obesity drugs, cancer immunotherapy, rare disease treatments, and personalized medicine. Companies at the top of the 2026 Pharm Exec 50 are expected to drive mergers and acquisitions, equipment upgrades, and new plant investments worldwide.

What Equipment Do These Pharma Leaders Use?

Most companies in this ranking run large oral solid dosage (OSD) operations alongside biologics. Their tablet and capsule plants are built around a similar process chain, and each step needs GMP-grade equipment that produces repeatable batches. We cover this in detail in what equipment the global Top 50 pharma companies use to ensure quality.

Process step Purpose Related JIANPAI equipment
Wet granulation Densify powders and improve flow and content uniformity High shear mixer granulators (JHZ-C, JHZ-D)
Drying Reduce granule moisture to the validated level Fluid bed dryers (JFG-C)
Sizing and milling Control particle size before blending Pharma mills (JZL sizing granulator)
Blending Mix granules with lubricants and excipients Pharma blenders (JPH three-eccentricity mixer)
Coating Film, sugar or enteric coating of tablets Tablet coating machines (JGB-D, JGB-E)
Integrated lines Closed, linked granulation lines that reduce manual handling Totally enclosed granulating production line, continuous manufacturing

Generic and contract manufacturers that supply these leaders, or compete with them, often benchmark their own lines against the same standards. For budget planning, see our tablet coating machine price guide.

Conclusion

The 2026 Global Top 50 Pharmaceutical Companies Ranking provides a clear overview of the world’s leading drug manufacturers, based on 2025 prescription drug sales, and reflects the direction of the global pharmaceutical industry. From biologics and oncology to diabetes, obesity, and rare disease therapies, these top companies will continue to drive innovation, capacity expansion, and equipment upgrades worldwide.

As a professional pharmaceutical machinery manufacturer, JIANPAI closely follows the development trends of these global pharma leaders and is committed to providing reliable, high-efficiency production and processing solutions for pharmaceutical manufacturers across the world. Whether you are planning a new production line, upgrading existing equipment, or expanding your formulation and packaging capacity, JIANPAI offers customized solutions to meet your exact needs.

FAQ

Who is the largest pharmaceutical company in the 2026 ranking?

Eli Lilly is No. 1 in the 2026 Pharm Exec 50, with about $60.8 billion in 2025 prescription (Rx) drug sales. Johnson & Johnson is No. 2. The complete Top 50 table above ranks companies by 2025 Rx sales, as described in the methodology section.

What equipment do top pharmaceutical companies use for oral solid dosage?

Large OSD plants typically run high shear wet granulation, fluid bed drying, milling and sizing, blending, tablet compression, and film or functional coating, often with closed material transfer and automated cleaning.

Why does this ranking matter for equipment suppliers?

Top companies set the quality and compliance expectations that generic and contract manufacturers follow. Equipment that meets their GMP, data integrity and containment needs is increasingly expected across the industry.

Planning an OSD line to global standards?

JIANPAI supplies granulation, drying, milling, blending and coating equipment for oral solid dosage plants. Send us your products and target capacity for a line proposal.

Email: [email protected] | Tel: +86 577-86932456 | No. 989 Lingde Road, Oujiangkou New District, Wenzhou, Zhejiang, China

en_USEN

Tell Us Your Requirements Questions Needs Ideas Plans